Gelidium elegans extract ameliorates type 2 diabetes via regulation of MAPK and PI3K/Akt signaling

Nutrients

Volumn 10, Issue 1, 2018, Pages

  Choi, Jia ^a   Kim, Kui Jin ^a   Koh, Eun Jeong ^a   Lee, Boo Yong ^a  

^a CHA University   (South Korea)

Author keywords

AKT; Diabetic symptoms; Gelidium elegans extract; Glucose uptake; MAPK pathways; Type 2 diabetes

Indexed keywords

ALGAL EXTRACT; GELIDIUM ELEGANS EXTRACT; GLUCOSE; GLUCOSE TRANSPORTER 4; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HBA(1C) PROTEIN, MOUSE; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, MOUSE; PHOSPHATIDYLINOSITOL 3 KINASE; PLANT EXTRACT; PROTEIN KINASE B; SLC2A4 PROTEIN, MOUSE;

ALGA; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; BODY MASS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FLUID INTAKE; FOOD INTAKE; GELIDIUM ELEGANS; MAPK SIGNALING; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PI3K/AKT SIGNALING; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; ISOLATION AND PURIFICATION; MALE; METABOLISM; PHOSPHORYLATION; RED ALGA; SIGNAL TRANSDUCTION; TIME FACTOR;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE TRANSPORTER TYPE 4; GLYCATED HEMOGLOBIN A; HYPOGLYCEMIC AGENTS; INSULIN RECEPTOR SUBSTRATE PROTEINS; MALE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS C-AKT; RHODOPHYTA; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 85040545728     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu10010051     Document Type: Article

References (65)

1. Musselman, D.L.; Betan, E.; Larsen, H.; Phillips, L.S. Relationship of depression to diabetes types 1 and 2: Epidemiology, biology, and treatment. Biol. Psychiatry 2003, 54, 317–329.
2. Burge, M.R.; Schade, D.S. Diabetes and the Affordable Care Act; Mary Ann Liebert, Inc.: New Rochelle, NY, USA, 2014.
3. Cnop, M.; Welsh, N.; Jonas, J.‐C.; Jörns, A.; Lenzen, S.; Eizirik, D.L. Mechanisms of pancreatic β‐cell death in type 1 and type 2 diabetes. Diabetes 2005, 54, S97–S107.
4. DeFronzo, R.A.; Ferrannini, E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14, 173– 194.
5. Robinson, M.J.; Cobb, M.H. Mitogen‐activated protein kinase pathways. Curr. Opin. Cell Biol. 1997, 9, 180– 186.
6. Li, S.; Brown, M.S.; Goldstein, J.L. Bifurcation of insulin signaling pathway in rat liver: MTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc. Natl. Acad. Sci. USA 2010, 107, 3441–3446.
7. Harrington, L.S.; Findlay, G.M.; Gray, A.; Tolkacheva, T.; Wigfield, S.; Rebholz, H.; Barnett, J.; Leslie, N.R.; Cheng, S.; Shepherd, P.R. The TSC1‐2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins. J. Cell Biol. 2004, 166, 213–223.
8. Khorami, S.A.H.; Movahedi, A.; Khaza’ai, H.; Mutalib, A.; Sokhini, M. PI3K/AKT pathway in modulating glucose homeostasis and its alteration in diabetes. AMBS 2015, 1, 46–55.
9. Sano, H.; Eguez, L.; Teruel, M.N.; Fukuda, M.; Chuang, T.D.; Chavez, J.A.; Lienhard, G.E.; McGraw, T.E. Rab10, a target of the AS160 Rab GAP, is required for insulin‐stimulated translocation of GLUT4 to the adipocyte plasma membrane. Cell Metab. 2007, 5, 293–303.
10. Kraegen, E.W.; Clark, P.W.; Jenkins, A.B.; Daley, E.A.; Chisholm, D.J.; Storlien, L.H. Development of muscle insulin resistance after liver insulin resistance in high‐fat–fed rats. Diabetes 1991, 40, 1397–1403.
11. Guilherme, A.; Virbasius, J.V.; Puri, V.; Czech, M.P. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 2008, 9, 367–377.
12. DeFronzo, R.A.; Tripathy, D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009, 32 (Suppl. 2), S157–S163.
13. Aksamitiene, E.; Kiyatkin, A.; Kholodenko, B.N. Cross‐Talk between Mitogenic Ras/MAPK and Survival PI3K/Akt Pathways: A Fine Balance; Portland Press Limited: London, UK, 2012.
14. Miyoshi, H.; Kato, K.; Iwama, H.; Maeda, E.; Sakamoto, T.; Fujita, K.; Toyota, Y.; Tani, J.; Nomura, T.; Mimura, S. Effect of the anti‐diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int. J. Oncol. 2014, 45, 322–332.
15. Hampp, C.; Borders-Hemphill, V.; Moeny, D.G.; Wysowski, D.K.Use of antidiabetic drugs in the US, 2003– 2012. Diabetes Care 2014, 37, 1367–1374.
16. Doran, E.; Halestrap, A.P. Evidence that metformin exerts its anti‐diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000, 348, 607–614.
17. Kramer, D.; Shapiro, R.; Adler, A.; Bush, E.; Rondinone, C. Insulin‐sensitizing effect of rosiglitazone (BRL‐ 49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 2001, 50, 1294– 1300.
18. Sugiyama, Y.; Taketomi, S.; Shimura, Y.; Ikeda, H.; Fujita, T. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Arzneimittelforschung 1990, 40, 263–267.
19. Singh, S.; Loke, Y.K.; Furberg, C.D. Long‐term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA 2007, 298, 1189–1195.
20. Schuster, D.P.; Duvuuri, V. Diabetes mellitus. Clin. Podiatr. Med. Surg. 2002, 19, 79–107.
21. Tunnicliffe, J.M.; Shearer, J. Coffee, glucose homeostasis, and insulin resistance: Physiological mechanisms and mediators. Appl. Physiol. Nutr. Metab. 2008, 33, 1290–1300.
22. Kim, K.‐J.; Yoon, K.‐Y.; Lee, B.‐Y. Fucoidan regulate blood glucose homeostasis in C57BL/KSJ m+/+ db and C57BL/KSJ db/db mice. Fitoterapia 2012, 83, 1105–1109.
23. Hannan, J.; Ali, L.; Rokeya, B.; Khaleque, J.; Akhter, M.; Flatt, P.; Abdel-Wahab, Y. Soluble dietary fibre fraction of Trigonella foenum‐graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action. Br. J. Nutr. 2007, 97, 514–521.
24. Kang, S.‐I.; Jin, Y.‐J.; Ko, H.‐C.; Choi, S.‐Y.; Hwang, J.‐H.; Whang, I.; Kim, M.‐H.; Shin, H.‐S.; Jeong, H.‐B.; Kim, S.‐J. Petalonia improves glucose homeostasis in streptozotocin‐induced diabetic mice. Biochem. Biophys. Res. Commun. 2008, 373, 265–269.
25. Pari, L.; Satheesh, M.A. Effect of pterostilbene on hepatic key enzymes of glucose metabolism in streptozotocin‐and nicotinamide‐induced diabetic rats. Life Sci. 2006, 79, 641–645.
26. Soufi, F.; Sheervalilou, R.; Vardiani, M.; Khalili, M.; Alipour, M. Chronic resveratrol administration has beneficial effects in experimental model of type 2 diabetic rats. Endocr. Regul. 2012, 46, 83–90.
27. Weisberg, S.P.; Leibel, R.; Tortoriello, D.V. Dietary curcumin significantly improves obesity‐associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008, 149, 3549–3558.
28. Kim, M.S.; Kim, J.Y.; Choi, W.H.; Lee, S.S. Effects of seaweed supplementation on blood glucose concentration, lipid profile, and antioxidant enzyme activities in patients with type 2 diabetes mellitus. Nutr. Res. Pract. 2008, 2, 62–67.
29. Kang, M.‐C.; Wijesinghe, W.; Lee, S.‐H.; Kang, S.‐M.; Ko, S.‐C.; Yang, X.; Kang, N.; Jeon, B.‐T.; Kim, J.; Lee, D.‐H. Dieckol isolated from brown seaweed Ecklonia cava attenuates type ІІ diabetes in db/db mouse model. Food Chem. Toxicol. 2013, 53, 294–298.
30. Maeda, H.; Hosokawa, M.; Sashima, T.; Miyashita, K. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. J. Agric. Food Chem. 2007, 55, 7701–7706.
31. Kang, M.C.; Kang, N.; Kim, S.Y.; Lima, I.S.; Ko, S.C.; Kim, Y.T.; Kim, Y.B.; Jeung, H.D.; Choi, K.S.; Jeon, Y.J. Popular edible seaweed, Gelidium amansii prevents against diet‐induced obesity. Food Chem. Toxicol. 2016, 90, 181–187.
32. Choi, J.; Kim, K.J.; Koh, E.J.; Lee, B.Y. Gelidium elegans Regulates the AMPK‐PRDM16‐UCP‐1 Pathway and Has a Synergistic Effect with Orlistat on Obesity‐Associated Features in Mice Fed a High‐Fat Diet. Nutrients 2017, 9, 342.
33. Choi, J.; Kim, K.‐J.; Koh, E.‐J.; Lee, B.‐Y. Altered Gelidium elegans extract‐stimulated beige‐like phenotype attenuates adipogenesis in 3T3‐L1 cells. J. Food Nutr. Res. 2016, 4, 448–453.
34. Jeon, H.J.; Seo, M.J.; Choi, H.S.; Lee, O.H.; Lee, B.Y. Gelidium elegans, an Edible Red Seaweed, and Hesperidin Inhibit Lipid Accumulation and Production of Reactive Oxygen Species and Reactive Nitrogen Species in 3T3‐L1 and RAW264.7 Cells. Phytother. Res. 2014, 28, 1701–1709.
35. Choi, J.; Kim, K.‐J.; Koh, E.‐J.; Seo, Y.‐J.; Lee, B.‐Y. Gelidium elegans Regulates Blood Glucose Homeostasis in ICR Mice. J. Food Nutr. Res. 2017, 5, 274–280.
36. Kim, M.; Lim, J.; Youn, H.; Hong, Y.; Yang, K.; Park, H.; Chung, S.; Koh, S.; Shin, S.; Choi, B. Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK– SIRT1–PGC1α axis in db/db mice. Diabetologia 2013, 56, 204–217.
37. Burke, S.J.; Batdorf, H.M.; Burk, D.H.; Noland, R.C.; Eder, A.E.; Boulos, M.S.; Karlstad, M.D.; Jason Collier, J. db/db Mice Exhibit Features of Human Type 2 Diabetes That Are Not Present in Weight‐Matched C57BL/6J Mice Fed a Western Diet. J. Diabetes Res. 2017, 2017, 116–132.
38. Nishina, P.M.; Lowe, S.; Wang, J.; Paigen, B. Characterization of plasma lipids in genetically obese mice: The mutants obese, diabetes, fat, tubby, and lethal yellow. Metabolism 1994, 43, 549–553.
39. Harlow, E.; Lane, D. Antibodies: A Laboratory Manual; Cold Spring Harbor Press: Cold Spring Harbor, NY, USA, 1988; pp. 139–245.
40. Worthington, D.R.; Brown, S.J. Diabetes Management System and Method for Controlling Blood Glucose. USRE43316 E1, 17 April 2012.
41. Ma, D.L.; Chen, F.Q.; Xu, W.J.; Yue, W.Z.; Yuan, G.; Yang, Y. Early intervention with glucagon‐like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice. J. Neurochem. 2015, 135, 301–308.
42. Pruessner, J.C.; Kirschbaum, C.; Meinlschmid, G.; Hellhammer, D.H. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time‐dependent change. Psychoneuroendocrinology 2003, 28, 916–931.
43. Nauck, M.A.; Heimesaat, M.M.; Orskov, C.; Holst, J.J.; Ebert, R.; Creutzfeldt, W. Preserved incretin activity of glucagon‐like peptide 1 [7‐36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type‐2 diabetes mellitus. J. Clin. Investig. 1993, 91, 301–307.
44. Rohlfing, C.L.; Little, R.R.; Wiedmeyer, H.‐M.; England, J.D.; Madsen, R.; Harris, M.I.; Flegal, K.M.; Eberhardt, M.S.; Goldstein, D.E. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the US population. Diabetes Care 2000, 23, 187–191.
45. Wallberg-Henriksson, H.; Zierath, J.R. GLUT4: A key player regulating glucose homeostasis? Insights from transgenic and knockout mice. Mol. Membr. Biol. 2001, 18, 205–211.
46. Liu, M.‐L.; Gibbs, E.M.; McCoid, S.C.; Milici, A.; Stukenbrok, H.A.; McPherson, R.K.; Treadway, J.L.; Pessin, J.E. Transgenic mice expressing the human GLUT4/muscle‐fat facilitative glucose transporter protein exhibit efficient glycemic control. Proc. Natl. Acad. of Sci. USA 1993, 90, 11346–11350.
47. Carvalho, E.; Jansson, P.‐A.; Nagaev, I.; Wenthzel, A.‐M.; Smith, U. Insulin resistance with low cellular IRS-1 expression is also associated with low GLUT4 expression and impaired insulin-stimulated glucose transport. FASEB J. 2001, 15, 1101–1103.
48. Tremblay, F.; Lavigne, C.; Jacques, H.; Marette, A. Defective insulin‐induced GLUT4 translocation in skeletal muscle of high fat–fed rats is associated with alterations in both Akt/protein kinase B and atypical protein kinase C (ζ/λ) activities. Diabetes 2001, 50, 1901–1910.
49. Jeon, H.‐J.; Yoon, K.‐Y.; Koh, E.‐J.; Choi, J.; Kim, K.‐J.; Choi, H.‐S.; Lee, B.‐Y. Seapolynol and Dieckol Improve Insulin Sensitivity through the Regulation of the PI3K Pathway in C57BL/KsJ‐db/db Mice. J. Food Nutr. Res. 2015, 3, 648–652.
50. Gogg, S.; Smith, U.; Jansson, P.‐A. Increased MAPK activation and impaired insulin signaling in subcutaneous microvascular endothelial cells in type 2 diabetes: The role of endothelin-1. Diabetes 2009, 58, 2238–2245.
51. Zhou, J.; Xu, G.; Ma, S.; Li, F.; Yuan, M.; Xu, H.; Huang, K. Catalpol ameliorates high‐fat diet‐induced insulin resistance and adipose tissue inflammation by suppressing the JNK and NF‐κB pathways. Biochem. Biophys. Res. Commun. 2015, 467, 853–858.
52. Weyer, C.; Bogardus, C.; Mott, D.M.; Pratley, R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Investig. 1999, 104, 787–794.
53. Cline, G.W.; Petersen, K.F.; Krssak, M.; Shen, J.; Hundal, R.S.; Trajanoski, Z.; Inzucchi, S.; Dresner, A.; Rothman, D.L.; Shulman, G.I. Impaired glucose transport as a cause of decreased insulin‐stimulated muscle glycogen synthesis in type 2 diabetes. New Engl. J. Med. 1999, 341, 240–246.
54. Abel, E.D.; Peroni, O.; Kim, J.K.; Young-Bum, K. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001, 409, 729–733.
55. Carvalho, E.; Kotani, K.; Peroni, O.D.; Kahn, B.B. Adipose-specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle. Am. J. Physiol. Endocrinol. Metab. 2005, 289, E551–E561.
56. Kerouz, N.J.; Hörsch, D.; Pons, S.; Kahn, C.R. Differential regulation of insulin receptor substrates‐1 and‐2 (IRS‐1 and IRS‐2) and phosphatidylinositol 3‐kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J. Clin. Investig. 1997, 100, 3164–3172.
57. Khamzina, L.; Veilleux, A.; Bergeron, S.; Marette, A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: Possible involvement in obesity‐linked insulin resistance. Endocrinology 2005, 146, 1473–1481.
58. Chen, K.; Li, G.; Geng, F.; Zhang, Z.; Li, J.; Yang, M.; Dong, L.; Gao, F. Berberine reduces ischemia/reperfusion-induced myocardial apoptosis via activating AMPK and PI3K–Akt signaling in diabetic rats. Apoptosis 2014, 19, 946–957.
59. Schultze, S.M.; Hemmings, B.A.; Niessen, M.; Tschopp, O. PI3K/AKT, MAPK and AMPK signalling: Protein kinases in glucose homeostasis. Expert Rev. Mol. Med. 2012, 14, e1.
60. Ponugoti, B.; Dong, G.; Graves, D.T. Role of forkhead transcription factors in diabetes‐induced oxidative stress. Exp. Diabetes Res. 2012, 2012, 567‐575.
61. Rondinone, C.M.; Wang, L.‐M.; Lonnroth, P.; Wesslau, C.; Pierce, J.H.; Smith, U. Insulin receptor substrate (IRS) 1 is reduced and IRS‐2 is the main docking protein for phosphatidylinositol 3‐kinase in adipocytes from subjects with non‐insulin‐dependent diabetes mellitus. Proc. Natl. Acad. Sci. USA 1997, 94, 4171–4175.
62. Aguirre, V.; Uchida, T.; Yenush, L.; Davis, R.; White, M.F. The c‐Jun NH2‐terminal kinase promotes insulin resistance during association with insulin receptor substrate‐1 and phosphorylation of Ser307. J. Biol. Chem. 2000, 275, 9047–9054.
63. Goodpaster, B.H.; Thaete, F.L.; Simoneau, J.‐A.; Kelley, D.E. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997, 46, 1579–1585.
64. Zhang, B.; Graziano, M.P.; Doebber, T.W.; Leibowitz, M.D.; White-Carrington, S.; Szalkowski, D.M.; Hey, P.J.; Wu, M.; Cullinan, C.A.; Bailey, P. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J. Biol. Chem. 1996, 271, 9455– 9459.
65. Gross, J.L.; Kramer, C.K.; Leitão, C. B.; Hawkins, N.; Viana, L.V.; Schaan, B.D.; Pinto, L.C.; Rodrigues, T.C.; Azevedo, M.J. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: A network meta‐analysis. Ann. Intern. Med. 2011, 154, 672–679.